13 completed, 4 terminated, 1 active not recruiting, 1 suspended. 19 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 13, Terminated 4, Active not recruiting 1, Suspended 1 |
| Phase 2 | 6 | Completed 4, Terminated 2 |
Follow Vismodegib: new trials by email Literature Review of Vismodegib trials Research Report on Vismodegib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer Atezolizumab, Biospecimen Collection, Computed Tomography - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Suspended | Dwight Owen | 24 | 2024-12-31 | 2026-09-18 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| NCT Neuro Master Match - N²M² (NOA-20) APG101, Alectinib, Idasanutlin - Glioblastoma, Adult | Phase 1 / Phase 2 | Completed | University Hospital Heidelberg | 228 | 2018-05-07 | 2023-09-28 |
| Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer Pembrolizumab, Vismodegib - Skin Basal Cell Carcinoma | Phase 1 / Phase 2 | Completed | Anne Chang | 16 | 2016-02-01 | 2019-03-08 |
| A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF) Placebo, Ruxolitinib, Vismodegib - Myelofibrosis | Phase 1 | Completed | Hoffmann-La Roche | 10 | 2016-01-25 | 2018-05-11 |
| A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis Pirfenidone, Vismodegib - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Hoffmann-La Roche | 21 | 2016-01-15 | 2017-10-30 |
| Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas Vismodegib - Basal Cell Carcinoma | Phase 1 | Completed | University of Arizona | 4 | 2015-11-30 | 2018-07-18 |
| A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib fluconazole, itraconazole, rabeprazole - Healthy Volunteer | Phase 1 | Completed | Genentech, Inc. | 92 | 2013-02-01 | 2016-11-02 |
| Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway vismodegib, Temozolomide - Histologically Confirmed Medulloblastoma, Activation of the Sonic Hedgehog (SHH) Pathway | Phase 1 / Phase 2 | Terminated | Centre Leon Berard | 24 | 2012-06-01 | 2019-05-21 |
| Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery vismodegib, sirolimus, positron emission tomography - Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas | Phase 1 | Completed | Mayo Clinic | 31 | 2012-03-05 | 2019-04-08 |
| A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function Vismodegib - Cancer | Phase 1 | Completed | Genentech, Inc. | 31 | 2012-03-01 | 2016-05-23 |
| Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma Vismodegib, Pharmacological Study, Laboratory Biomarker Analysis - DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma | Phase 1 | Completed | National Cancer Institute (NCI) | 50 | 2010-12-01 | 2014-12-23 |
| A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists Vismodegib, Rosiglitazone, Norethindrone/ethinyl estradiol - Solid Cancers | Phase 1 | Completed | Genentech, Inc. | 52 | 2010-11-01 | 2015-06-29 |
| Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate - Prostate Adenocarcinoma, Stage IIA Prostate Cancer AJCC v7 | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 10 | 2010-07-09 | 2019-02-28 |
| Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2010-06-01 | 2018-08-15 |
| RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacogenomic Study - Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Terminated | National Cancer Institute (NCI) | 13 | 2009-11-01 | 2015-04-15 |
| Evaluation of Food Effect on Pharmacokinetics of Vismodegib Pharmacological Study, Vismodegib - Malignant Neoplasm | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 63 | 2009-10-01 | 2017-05-19 |
| GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery Diagnostic Laboratory Biomarker Analysis, Erlotinib Hydrochloride, Gemcitabine Hydrochloride - Adult Solid Neoplasm, Pancreatic Acinar Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 55 | 2009-03-31 | 2026-11-18 |
| GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment vismodegib, laboratory biomarker analysis, pharmacological study - Recurrent Childhood Medulloblastoma | Phase 1 | Completed | National Cancer Institute (NCI) | 34 | 2009-01-01 | 2014-04-02 |
Pancreatic Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Basal Cell (2) · Medulloblastoma (2) · Multiple Myeloma (2) · Neoplasms (2) · Primary Myelofibrosis (2) · Prostatic Neoplasms (2) · Anemia (1) · Blast Crisis (1) · Carcinoma, Non-Small-Cell Lung (1) · Chondrosarcoma (1) · Chondrosarcoma, Extraskeletal Myxoid (1) · Dermatofibrosarcoma (1) · Desmoplastic Small Round Cell Tumor (1)
National Cancer Institute (NCI) (7) · Genentech, Inc. (3) · Hoffmann-La Roche (2) · Anne Chang (1) · Centre Leon Berard (1) · Dwight Owen (1) · Mayo Clinic (1) · OHSU Knight Cancer Institute (1) · University Hospital Heidelberg (1) · University of Arizona (1)
United States (17) · Germany (3) · Italy (2) · Canada (1) · France (1) · Switzerland (1) · United Kingdom (1)
Amar Gajjar (1) · Anne Lynn S Chang, MD (1) · Carol Huff (1) · Charles Erlichman (1) · Charles Erlichman, M.D. (1) · Christopher Logothetis (1) · Dawn Colburn, Pharm.D. (1) · Dwight H Owen, MD (1) · Lara Davis, MD (1) · Manish Sharma (1) · Mariette Marsh (1) · Mrinal Gounder (1) · Patricia LoRusso (1) · Wolfgang Wick, Prof. Dr. (1)
PMID 20818327, PMID 27154174, PMID 30249277, PMID 32026407, PMID 39863139, PMID 40913172
2015 (3), U01CA070095 (2), N01CM00039 (1), N01CM62202 (1), N01CM62206 (1), P30CA006973 (1), P30CA008748 (1), P30CA014599 (1), P30CA015083 (1), P30CA016672 (1), P30CA022453 (1), P30CA124435 (1), P50CA102701 (1), U01CA062461 (1), U01CA062487 (1)